INBRX-106 + pembrolizumab + carboplatin + paclitaxel

**INBRX-106 + pembrolizumab + carboplatin + paclitaxel** is an investigational multi-agent combination regimen being evaluated primarily for the treatment of locally advanced or metastatic solid tumors, especially non-small cell lung cancer (NSCLC)[2][6]. INBRX-106 is a hexavalent agonist antibody specifically designed to cluster and activate the OX40 receptor (CD134) on T cells, thereby enhancing immune activation against tumors[1][3]. Pembrolizumab is a humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1) checkpoint, releasing inhibitory signaling and restoring antitumor immunity. Carboplatin and paclitaxel are cytotoxic chemotherapeutics: carboplatin alkylates DNA, while paclitaxel stabilizes microtubules, leading to apoptosis in rapidly dividing tumor cells[6]. Combined, this regimen pursues immune costimulation (OX40), checkpoint blockade (PD-1), and broad cytotoxicity. This approach is currently under phase 1/2 clinical evaluation, with safety, tolerability, and antitumor activity as primary end points[1][2][4][6].

Other names

pembrolizumabcarboplatinpaclitaxel